Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21357046 | 0.91 | — | — | |
| SCHEMBL30368963 | 0.91 | TSHR (0.39) | NPC1HTTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL30368740 | 0.91 | TSHR (0.39) | NPC1HTTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL1297693 | 0.91 | TSHR (0.39) | NPC1HTTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL1297690 | 0.83 | LMNA (0.42) | NPC1HTTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL27699230 | 0.83 | SMN1; SMN2 (0.42) | HTTSMN1; SMN2L3MBTL1TSHRMAPT | |
| SCHEMBL1297364 | 0.82 | GAA (0.44) | NPC1RAB9ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL15071090 | 0.82 | PPM1B (0.49) | SMN1; SMN2MAPTPPM1BPTPN1PPP1CC | |
| SCHEMBL20272016 | 0.82 | PPM1B (0.49) | SMN1; SMN2MAPTPPM1BPTPN1PPP1CC | |
| SCHEMBL20267266 | 0.82 | PPM1B (0.49) | SMN1; SMN2MAPTPPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46698-E1 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-RE46698-E1 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9492364-B2 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-9492364-B2 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| WO-2015082034-A1 | USE OF CYCLOHEXANOIC ACID DERIVATIVES AS PLASTICIZERS | MERCK PATENT GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| WO-2013091775-A2 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE INGREDIENTS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | CYP51A1, DDT, EBP | NPC1 630/4885HTT 837/4885RAB9A 3312/4885 |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | CYP51A1, DDT, EBP | NPC1 630/4885HTT 837/4885RAB9A 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.